NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,295,097 | -26.9% | 546,450 | -7.1% | 0.00% | -100.0% |
| Q2 2023 | $5,874,369 | +4.8% | 588,025 | -6.8% | 0.00% | 0.0% |
| Q1 2023 | $5,605,091 | -29.3% | 631,204 | -12.5% | 0.00% | 0.0% |
| Q4 2022 | $7,922,498 | +366.6% | 721,539 | +453.6% | 0.00% | – |
| Q3 2022 | $1,698,000 | +52.6% | 130,341 | +48.4% | 0.00% | – |
| Q2 2022 | $1,113,000 | +51.2% | 87,814 | +67.1% | 0.00% | – |
| Q1 2022 | $736,000 | -71.3% | 52,550 | -40.6% | 0.00% | – |
| Q4 2021 | $2,562,000 | +13.9% | 88,515 | +17.9% | 0.00% | – |
| Q3 2021 | $2,249,000 | +203.9% | 75,072 | +169.0% | 0.00% | – |
| Q2 2021 | $740,000 | -23.9% | 27,909 | -10.8% | 0.00% | – |
| Q1 2021 | $973,000 | +307.1% | 31,304 | +331.4% | 0.00% | – |
| Q4 2020 | $239,000 | -19.8% | 7,257 | -14.8% | 0.00% | – |
| Q3 2020 | $298,000 | – | 8,519 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |